You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

386 Results
Statistical Reports
Oct 2020
Statistical Reports
Sep 2016
Statistical Reports
Sep 2015
Cancer facts
Oct 2020
Statistical Reports
Apr 2018
Guidelines and Advice
Status: Current
Apr 2020
Guidelines and Advice
Status: Current
Oct 2019
Document
Oct 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
ifosfamide,
mesna,
CARBOplatin,
etoposide,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Document
Feb 2021
Document
Feb 2021
Document
Mar 2021

Pages